The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Thomas A. Waldmann

Metabolism Branch

Center for Cancer Research

National Cancer Institute (NCI)

National Institutes of Health (NIH)

USA

[email]@helix.nih.gov

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Metabolism Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), USA. 2003 - 2013
  • National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 1998 - 2006
  • National Institutes of Health, National Cancer Institute, Bldg 10, Room 4N115, USA. 2003

References

  1. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. Waldmann, T.A., Conlon, K.C., Stewart, D.M., Worthy, T.A., Janik, J.E., Fleisher, T.A., Albert, P.S., Figg, W.D., Spencer, S.D., Raffeld, M., Decker, J.R., Goldman, C.K., Bryant, B.R., Petrus, M.N., Creekmore, S.P., Morris, J.C. Blood (2013) [Pubmed]
  2. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. Waldmann, T.A. J. Clin. Immunol. (2007) [Pubmed]
  3. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Waldmann, T.A. Oncogene (2007) [Pubmed]
  4. Effective cancer therapy through immunomodulation. Waldmann, T.A. Annu. Rev. Med. (2006) [Pubmed]
  5. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Waldmann, T.A. Nat. Rev. Immunol. (2006) [Pubmed]
  6. The meandering 45-year odyssey of a clinical immunologist. Waldmann, T.A. Annu. Rev. Immunol. (2003) [Pubmed]
  7. Immunotherapy: past, present and future. Waldmann, T.A. Nat. Med. (2003) [Pubmed]
  8. IL-15 in the life and death of lymphocytes: immunotherapeutic implications. Waldmann, T.A. Trends. Mol. Med (2003) [Pubmed]
  9. ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. Waldmann, T. Leuk. Lymphoma (2003) [Pubmed]
  10. The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases. Waldmann, T. Arthritis Res. (2002) [Pubmed]
  11. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Waldmann, T.A., Dubois, S., Tagaya, Y. Immunity (2001) [Pubmed]
  12. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Waldmann, T.A., Tagaya, Y. Annu. Rev. Immunol. (1999) [Pubmed]
  13. The use of antibodies against the IL-2 receptor in transplantation. Waldmann, T.A., O'Shea, J. Curr. Opin. Immunol. (1998) [Pubmed]
 
WikiGenes - Universities